Please login to the form below

Not currently logged in
Email:
Password:

Bayer seeks ACS approval for Xarelto

Bayer has said it intends to file Xarelto (rivaroxaban) for marketing approval in the treatment of patients with acute coronary syndrome (ACS)

Bayer has said it intends to file its blood thinner Xarelto (rivaroxaban) for marketing approval in the treatment of patients with acute coronary syndrome (ACS) by the end of 2011.

The announcement comes after a phase III trial that demonstrated that Xarelto plus standard therapy significantly reduced the rate of events for the study's primary endpoint of cardiovascular death, myocardial infarction and stroke in patients with ACS.

However, Xarelto also demonstrated a significant increase in major bleeding events not associated with coronary artery bypass graft surgery – the primary safety endpoint of the trial.

Xarelto, which Bayer is co-developing with Johnson & Johnson, is already approved for the prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.

The US Food and Drug Administration (FDA) recently recommended the drug for use in stroke prevention in patients with the heart condition nonvalvular atrial fibrillation.

3rd October 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

It’s all about patient outcomes… right?
Lessons from history: a design thinking perspective...
Emma Walmsley 2
30 Women Leaders in UK Healthcare (part 3)
Continuing our special feature on Women Leaders in UK Healthcare...
Louise Houson
30 Women Leaders in UK Healthcare
The enormous challenges facing UK healthcare mean it needs great leaders. PME’s Group Editor Andrew McConaghie introduces 30 outstanding innovators and trailblazers helping to shape the future...

Infographics